# Bumetanide

Drug · id `cardio:bumetanide` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Bumex

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Heart failure; Kidney connections  

## In plain language

Bumetanide, sold as Bumex, is a loop diuretic, a medicine taken by mouth that acts on the kidney. The US label read, for Bumex tablets, lists swelling from fluid build-up in people with congestive heart failure, liver disease and kidney disease, including the nephrotic syndrome. The label carries a boxed warning that the medicine is a potent diuretic and, in excessive amounts, can lead to a profound loss of water and salts from the body.

## Technical summary

RxNorm ingredient 1808; UNII 0Y2S3XUQ5H. MeSH descriptor D002034 is Bumetanide. Class: Loop Diuretic (FDA established pharmacologic class, RxClass). The label read is the Validus Pharmaceuticals LLC label for Bumex tablets, application NDA018225, effective 2025-09-08 in openFDA. Bumetanide injection labels (for example ANDA applications) and generic labels were not read. The label says safety and effectiveness in patients under 18 have not been established; that statement was not recorded as a claim. This page records label indications, the title and first sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with edema from congestive heart failure, liver disease or kidney disease, as described in the US label of Bumex tablets

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: people with edema associated with congestive heart failure, hepatic disease or renal disease, including the nephrotic syndrome. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Bumex (bumetanide tablets, Validus Pharmaceuticals LLC, application NDA018225; the version dated 2025-09-08 in openFDA) lists the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It describes bumetanide as a loop diuretic. The label carries a boxed warning that the medicine is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: people with edema associated with congestive heart failure, hepatic disease or renal disease, including the nephrotic syndrome. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for and the boxed warning's first sentence. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning goes on to say what prescribers must do; that instruction is not repeated here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Bumex (bumetanide tablets), Validus Pharmaceuticals LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (manufacturer Validus Pharmaceuticals LLC, application NDA018225), returned on 2026-11-18. The label text is dated 2025-09-08 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2232dfbea3-eb2b-4070-8605-57ce3e6d5a2f%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:08Z. Source state: Current. Version fingerprint: 6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Bumex (bumetanide tablets), Validus Pharmaceuticals LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (manufacturer Validus Pharmaceuticals LLC, application NDA018225), returned on 2026-11-18. The label text is dated 2025-09-08 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2232dfbea3-eb2b-4070-8605-57ce3e6d5a2f%22&limit=1>
     Locator: results\[0\].clinical\_pharmacology\[0\], first sentence. Retrieved 2026-11-18T17:27:08Z. Source state: Current. Version fingerprint: 6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for Bumex (bumetanide tablets), Validus Pharmaceuticals LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (manufacturer Validus Pharmaceuticals LLC, application NDA018225), returned on 2026-11-18. The label text is dated 2025-09-08 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2232dfbea3-eb2b-4070-8605-57ce3e6d5a2f%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first sentence. Retrieved 2026-11-18T17:27:08Z. Source state: Current. Version fingerprint: 6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Background: openFDA drug label record for Bumex (bumetanide tablets), Validus Pharmaceuticals LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (manufacturer Validus Pharmaceuticals LLC, application NDA018225), returned on 2026-11-18. The label text is dated 2025-09-08 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2232dfbea3-eb2b-4070-8605-57ce3e6d5a2f%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:08Z. Source state: Current. Version fingerprint: 6097bcd5b6638cd4d11c8aea78439d1b9d73e8e69002fdc2f0399cadd90f1455.
     How it applies: Effective date of the label text read, 20250908.

## Connected pages

- Bumetanide is a loop diuretic (FDA established pharmacologic class in RxClass): Loop diuretics (`cardio:loop-diuretics`)
- FDA label lists edema associated with congestive heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-bumetanide-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: d4dacfb3343cd13e17db6e2964c75fdd1284a8c7cfd111edf870e43c73e71515
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
